The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.75
Bid: 13.60
Ask: 13.90
Change: 0.15 (1.10%)
Spread: 0.30 (2.206%)
Open: 13.60
High: 13.75
Low: 13.75
Prev. Close: 13.60
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Kingswood cuts outlook; Poolbeg in patent joy

Mon, 02nd Oct 2023 14:20

(Alliance News) - The following is a round-up of updates by London-listed companies, issued last week and not separately reported by Alliance News:

----------

Kingswood Holdings Ltd - wealth manager - Cuts profit guidance. Kingswood's revenue in the half-year ended June 30 declines 22% to GBP80.4 million from GBP62.7 million and its pretax loss widens to GBP9.9 million from GBP1.7 million. Kingswood cuts its proforma operating profit guidance to GBP13.6 million from GBP14.7 million, due to lower than expected investment banking and capital markets activity.

----------

Poolbeg Pharma PLC - London-based infectious disease focused biopharmaceutical company - Says hearing with European Patent Office related to Immunomodulator I, one of its European patents, has been cancelled. "This favourably concludes this matter with the patent maintained as granted," Poolbeg adds.

----------

PHSC PLC - Kent-based health, safety, hygiene and environmental consultancy services provider - Says revenue for five-months ended August 31 falls to just shy of GBP1.4 million from GBP1.4 million a year prior. Earnings before interest, tax, depreciation, and amortisation down to GBP139,000, from GBP144,000. "This was caused by the lower revenues not being fully offset by reduced costs and the pay increases referred to above," PHSC says.

----------

Looking Glass Labs Ltd - specialises in metaverse, play-to-earn tokenisation and blockchain monetisation - Plans share consolidation. Every 75 shares to be consolidated into one share.

----------

Grand Vision Media Holdings PLC - out-of-home advertising and digital marketing company - Revenue in six months to June rises 21% to HKD2.3 million, around GBP237,829, from HKD1.9 million a year prior. Pretax loss narrows to HKD2.0 million from HKD2.3 million. Company says: "After the 3-year period shroud by Covid-19, the world enters a new post-pandemic era in 2023. However, the general market outlook continue to present many challenges due to tightening economic conditions in China and other global economies. We continue to diversify and look for new revenue streams and business models to augment our core marketing services. The new initiative of international brand management and expansion whereby we help brands expand to new geographies is progressing and we expect to generate revenue from this in the second half of the year. In particular, we will be working closely with our Korean and Thai customers to increase cross-border ecommerce."

----------

KR1 PLC - investor focused on the blockchain industry - Net asset value per share rises 67% year-on-year to 51.1 pence per share at its June 30 half-year end. NAV per share is 30% higher from December 31. "With some positive market momentum as well as major new investments that were announced since the year-end, the company's net assets have grown substantially to GBP90.7 million at the end of June, providing shareholders with capital growth, which remains our main long-term focus. The year-on-year decline in income from digital assets, driven by various factors, including stagnant prices over the relevant period, was expected, while still being of great benefit to the company."

----------

VVV Resources Ltd - investor focused on identifying opportunities in the precious metals and base metals sector - Pretax loss in half-year to June 30 narrows to GBP62,000 from GBP77,000 a year prior. Loss is solely down to administrative costs, which decline 19% to GBP62,000. Posts no revenue, unchanged from prior year.

----------

Octopus Titan VCT PLC - venture capital trust - Says will raise maximum of GBP125 million, with an over-allotment facility worth GBP75 million, in planned offer for subscription.

----------

One Heritage Group PLC - UK-based residential developer focused on the north of England - Completes sale of remaining 15 units at Lincoln House, Bolton, ahead of updated deadline of October 9. "The funds have been received in full, including an interest payment that the buyer had to pay," it says. In addition, One Heritage says Anthony Unsworth resigns as chief financial officer. One Heritage adds: "Anthony will continue in his role as CFO and executive director during his notice period during the next six months. The company has already begun speaking with its contacts in the headhunter world and has started the process of finding the right person for the next leg of the growth in the business."

----------

Cavendish Financial PLC - London-based stockbroker - Says trading in the City was "quiet during the summer", though Cavendish, established on September 8 via the merger of finnCap and Cenkos, has been busy since forming. Cavendish Financial adds: "Since merger completion the group has already announced a number of significant transactions which will close in the coming months including acting as sole adviser to Round Hill Royalty Fund Ltd on its offer from Concord Cadence Ltd, fundraisings for Haydale Graphene PLC and Shield Therapeutics plc and obtaining key regulatory clearances for the equity financing of Allergy Therapeutics by ZQ Capital and Southern Fox."

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
21 Dec 2022 19:20

TRADING UPDATES: Atlantis Japan underperforms; Bellevue lowers payout

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
21 Dec 2022 13:37

Poolbeg identifies new drug candidates with OneThree

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma has successfully identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) programme with OneThree Biotech, it announced on Wednesday.

Read more
14 Dec 2022 21:54

TRADING UPDATES: Poolbeg acquires license; Afentra expects PSA delay

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
14 Dec 2022 16:14

Poolbeg secures exclusive licence to possible obesity drug tech

(Sharecast News) - Infectious disease-focussed biopharmaceutical company Poolbeg Pharma has acquired an exclusive licence from AnaBio sister company InsuCaps, it announced on Wednesday, to use its patented microencapsulation and nanoencapsulation oral delivery technologies in metabolic syndrome-related diseases, including obesity, pre-diabetes and diabetes.

Read more
2 Dec 2022 19:33

TRADING UPDATES: Time Out eyes Riyadh; MTI Wireless wins deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued this week and not separately reported by Alliance News:

Read more
15 Nov 2022 17:25

Poolbeg Pharma wins funding for oral vaccine development

(Alliance News) - Poolbeg Pharma PLC on Tuesday said it has received funding from the Irish Government to improve the manufacturing, distribution and administration of its oral vaccines.

Read more
8 Nov 2022 13:06

Poolbeg announces 'breakthrough' in AI drug target programme

(Sharecast News) - Infectious disease pharmaceutical developer Poolbeg Pharma announced a "significant breakthrough" in its artificial intelligence (AI) programme with partner OneThree Biotech on Tuesday, through the discovery of novel drug targets for the treatment of respiratory syncytial virus (RSV).

Read more
8 Nov 2022 12:18

IN BRIEF: Poolbeg makes "significant breakthrough" in AI programme

Poolbeg Pharma PLC - London-based clinical stage infectious disease pharmaceutical company - Announces "significant breakthrough" in its artificial intelligence programme with its partner OneThree Biotech Inc, a New York-based drug discovery-focused firm. Says breakthrough is the discovery of novel drug targets for the treatment of respiratory syncytial virus. The identification of these targets allow for the final stages of the programme to start, Poolbeg explains. This will involve the identification of small molecule inhibitors to treat RSV infections. The team is "particularly excited", the firm says, as these include a range of targets for which there are known drugs with existing Phase I safety and tolerability data. Results are expected before the end of 2022.

Read more
4 Oct 2022 14:14

Poolbeg Pharma upbeat on US patent application progress

(Sharecast News) - Infectious disease pharmaceutical company Poolbeg Pharma updated the market on its intellectual property (IP) position around 'POLB 001' on Tuesday, which it described as a small molecule immunomodulator for the treatment of severe influenza.

Read more
4 Oct 2022 10:14

Poolbeg expects formal patent grant soon to treat hypercytokinemia

(Alliance News) - Poolbeg Pharma PLC on Tuesday said that the US Patent & Trademarks Office has indicated that its patent application concerning the use of POLB 001 and its homologues for the treatment of hypercytokinemia is allowable.

Read more
4 Oct 2022 08:46

LONDON MARKET OPEN: Stocks rise as market sentiment recovers

(Alliance News) - Stock prices in London opened sharply higher on Tuesday, lifted by more positive market sentiment following the UK government's tax U-turn, as well as some positive trading updates.

Read more
4 Oct 2022 07:52

LONDON BRIEFING: Pound, oil, gold up; Truss vows fiscal responsibility

(Alliance News) - Stocks in London are called higher on Tuesday, as the market watches closely for further clues regarding the UK's economic direction.

Read more
27 Sep 2022 06:59

IN BRIEF: Poolbeg Pharma teams up for Melioidosis vaccine

Poolbeg Pharma PLC - London-based pharmaceutical company - On Wednesday reported it a signed an in-license agreement for the development of a Melioidosis vaccine candidate with University College Dublin. Melioidosis is an infectious disease spread by a bacterium in contaminated soil or water. It has a minimum fatality rate of around 10% and no vaccine for the disease exists. Poolbeg's late preclinical stage vaccine candidate has the name POLB 003. It is being developed following several years of research.

Read more
21 Sep 2022 16:18

Poolbeg inks exclusive deal for melioidosis vaccine candidate

(Sharecast News) - Clinical-stage infectious disease pharmaceutical company Poolbeg Pharma has signed an exclusive licence agreement with University College Dublin (UCD), it announced on Wednesday, for a late preclinical-stage vaccine candidate for melioidosis.

Read more
6 Sep 2022 14:04

IN BRIEF: Poolbeg shares rises on narrowed loss, strong pipeline

Poolbeg Pharma PLC - London-based pharmaceutical company - In the six months ended June 30, narrows its pretax loss to GBP1.7 million from GBP2.3 million loss the year prior. Does not post a revenue figure, unchanged from the previous year. Research & development expenses rise to GBP657,000 from GBP414,000. Notes "significant" progress on POLB 001, its treatment for severe influenza. Expects outputs from its respiratory syncytial virus and influenza artificial intelligence programmes by the end of 2022 and the second quarter of 2023, respectively. Adds it has "strong financial resources available to progress its products and platforms."

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.